Feed Top Reports Pricing

⌘K

08:35:59·506d

ANALYSTRating

Morgan Stanley resumed coverage on BeiGene with a new price target

BGNE· BeiGene Ltd.

Health Care

Original source

Companies

BGNE
BeiGene Ltd.
Health Care

Recent analyst ratings

Dec 3UpdateMorgan Stanley$300.00
Sep 18UpdateJMP Securities$288.00
Feb 6UpdateJP Morgan$185.00
Sep 12UpdateMacquarie$259.00
Aug 17UpdateJefferies$287.00
Jul 17UpdateCitigroup$275.00

Related

PR389d
BeiGene Receives Positive CHMP Opinion for TEVIMBRA® as a First-Line Treatment for Extensive-Stage Small Cell Lung Cancer
PR482d
TEVIMBRA Approved in U.S. for First-line Treatment of Gastric and Gastroesophageal Junction Cancers in Combination with Chemotherapy
SEC486d
BeiGene Ltd. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
PR486d
BeiGene to Change Nasdaq Ticker Symbol to "ONC" on January 2; Present at 43rd Annual J.P. Morgan Healthcare Conference
INSIDER492d
Chief Executive Officer Oyler John exercised 1,300,000 units of Ordinary Shares at a strike of $0.50, increasing direct ownership by 77% to 2,978,833 units (SEC Form 4)
PR497d
BeiGene Announces Global Licensing Agreement for MAT2A Inhibitor
INSIDER497d
Chair, Scientific Advisory Brd Wang Xiaodong sold $7,805,106 worth of American Depositary Shares (41,760 units at $186.90) and exercised 41,760 units of American Depositary Shares at a strike of $6.50 (SEC Form 4)
13D/G499d
Amendment: SEC Form SC 13D/A filed by BeiGene Ltd.

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releases Analyst ratings Insider trading FDA SEC RSS feeds

Top lists

Trending By market cap Active companies Analyst upgrades Insider purchases FDA approvals SEC filings Sectors Market reports

Company

About Pricing Publish with us Contact

Legal

Terms of use Privacy policy Cookie policy

© 2026 quantisnow.com · Democratizing insights since 2022